GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

+1.69 (+1.68%)

Growth Price

Overvalued by 73.67%

Stability Price

Overvalued by 85.22%

Company Metrics

  • 22.83 P/E
  • 8.73 P/S
  • 9.53 P/B
  • 4.414 EPS
  • 39.33% Cash ROIC
  • 0.34 Cash Ratio
  • 0 / 0% Dividend
  • 14.46M Avg. Vol.
  • 154.9B Market Cap.

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph...

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


What Johnson & Johnson Can Tell Us about Gilead Sciences, inc. Stock
NASDAQ - 12 hours ago
Johnson & Johnson is one of the planet's biggest drugmakers. Its drugs are used for a variety of diseases, including cancer and autoimmune disorders, but it's J&J's sales of the hepatitis C drug Olysio that are most interesting to Gilead Sciences ...
Gilead: Stage Set For Rally (GILD) - Seeking Alpha (registration)
Johnson & Johnson, Domino's, Citigroup, Gilead Sciences and JPMorgan are ... - Times Colonist
Will Sagging Scripts Dent Gilead Sciences, Inc. Earnings?
Motley Fool - Oct 17, 2014
Gilead Sciences (NASDAQ: GILD ) has been the poster child for biotechnology success this year thanks to Sovaldi, its game-changing therapy for hepatitis C. However, there's a potential hiccup that could soon weigh on Gilead's shares.
Gileads Harvoni Receives Notice of Compliance from Canada -
Should Gilead Sciences, inc. Fear Incoming Competition?
Motley Fool - Oct 15, 2014
Gilead Sciences' (NASDAQ: GILD ) shares have tumbled more than 8% in the past week as investors digest the FDA approval of its second-generation hepatitis C drug Harvoni and the potential competitive threats from AbbVie (NYSE: ABBV ) and ...
Updating My Price Target On Gilead Sciences - Seeking Alpha (registration)
Health Canada Issues Notice of Compliance for Gilead's Harvoniā„¢ (Ledipasvir ... - MarketWatch
Gilead Sciences Inc. Gets First Hepatitis C Cocktail Drug Approved
Motley Fool - Oct 10, 2014
While the sales will bring in more for Gilead Sciences, insurers won't pay more because the cost is essentially the same as Sovaldi plus interferon and a third drug, ribavirin, which was taken concurrently.
Gilead Gets US Approval to Sell New Hepatitis C Drug - Wall Street Journal
FDA approves hepatitis C drug that costs $1125 per pill - Fox News
Gilead Sciences, Inc. Got 2 Drugs Approved, and Didn't Bother to Tell Anyone
Motley Fool - Oct 4, 2014
The Food and Drug Administration approved two new HIV drugs last week -- Tybost and Vitekta -- but Gilead Sciences (NASDAQ: GILD ) didn't even bother to issue a press release on its website.
Gilead Sciences, Inc. Reaches New Heights With Sovaldi
ValueWalk - Oct 3, 2014
Gilead Sciences, Inc. (NASDAQ:GILD) is a Foster City, California based bio-pharmaceutical company that discovers, develops and commercializes therapeutics for unmet medical areas in need.
Insider Selling: Gilead Sciences CEO Sells 140625 Shares of Stock (GILD) - Ticker Report
Insider Selling: Richard James Whitley Sells 5000 Shares of Gilead Sciences ... - sleekmoney
Johnson & Johnson Takes Aim at Gilead Sciences, inc.
Motley Fool - Oct 6, 2014
The acquisition could help energize Johnson & Johnson's hepatitis C program, positioning it to more directly compete with Gilead Sciences (NASDAQ: GILD ) , whose Sovaldi soundly trounced J&J's own Olysio after both drugs won FDA approval late last year ...
Gilead Sciences Outperforms Biotech Sector Over Success Of Sovaldi, Harvoni ... - Bidness ETC
Gilead: Catalysts In Place For A Big October (GILD) - Seeking Alpha (registration)
Gilead Sciences, Inc. Takes Aim at Bristol-Myers Squibb
Motley Fool - Sep 29, 2014
Excitement is growing ahead of the Food and Drug Administration's decision on Gilead Sciences (NASDAQ: GILD ) next generation hepatitis C treatment.
Why Gilead Sciences (GILD) Stock Is Declining Today -
France Will use Taxes to Pressure Drug Makers on Hep C Prices - Wall Street Journal (blog)
Bristol-Myers Tells Gilead Sciences, Inc. "You Win"
Motley Fool - Oct 8, 2014
Bristol-Myers Squibb's (NYSE: BMY ) shocking announcement that it's yanking its FDA application for approval of asunaprevir, effectively derailing it's promising two drug hepatitis C treatment, is a resounding victory for Gilead Sciences (NASDAQ: GILD ...
Gilead Sciences: Hitch Your Wagon To This Biotech Juggernaut Before It Really ... - Seeking Alpha (registration)
Gilead Sciences, Inc. (GILD), Apple Inc. (AAPL), Johnson & Johnson (JNJ ... - StockWise Daily
Gilead Sciences, Inc. Stock's Stunning New Opportunity
Motley Fool - Sep 30, 2014
Gilead is the king of the HIV business. Its wildly successful Sovaldi launch is without a doubt the biggest biotech event of the year.